linjc16/ctgov huggingface dataset:
Survey on Attitudes About COVID-19 Vaccinations in Italian HCW

Study Overview
=================
Brief Summary
-----------------
The Project is aimed at analyzing the perceptions, knowledge, attitudes and intentions of the population towards the anti-SARS-CoV-2 vaccine in order to identify the determinants of vaccine refusal/hesitancy, and to guide specific activities aimed at updating and the implementation of institutional communication strategies on the vaccine, involving health professionals and targeting the general population.

Official Title
-----------------
Survey on Attitudes About COVID-19 Vaccinations in a Survey of Italian Healthcare Workers

Conditions
-----------------
Vaccination Hesitancy

Intervention / Treatment
-----------------
* Behavioral: survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthcare workers residing in Italy Exclusion Criteria: healthcare workers not residing in Italy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: survey|administration of a survey among healthcare workers|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| KAB factors | Identify the factors associated with knowledge, attitudes and intentions towards the anti-SARS-CoV-2 vaccine and the appropriate vaccine hesitancy measurement tools based on the best scientific evidence for the construction of the survey questionnaire. | 4 months |
Evaluation of Pregnancy Associated Plasma Protein A (PAPPA) as a Biomarker in Breast Cancer.

Study Overview
=================
Brief Summary
-----------------
This work aims to: Evaluation of the role of pregnancy associated plasma protein A( PAPPA ) in diagnosis & early detection of breast cancer. Evaluation of the relationship between ( PAPPA ) levels and stages of breast cancer.

Official Title
-----------------
Evaluation of Pregnancy Associated Plasma Protein A (PAPPA) as a Biomarker in Breast Cancer.

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female patients with breast cancer who were diagnosed by histopathological studies and did not receive any treatment. Exclusion Criteria: Patients who received chemotherapy or radiotherapy. Patients with known other organ malignancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients diagnosed with breast cancer at different stages of the disease. | |
| 2<br>apparently healthy females as a control group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative measurement of pregnancy associated plasma protein A in female patients with breast cancer. | Quantitative measurement of pregnancy associated plasma protein A in female patients with breast cancer. | baseline |
KINO-DYSPNEA: Validation of Kinocardiography to Distinguish Dyspnea of Cardiac Origin From Others

Study Overview
=================
Brief Summary
-----------------
Seismocardiography (SCG) measures the thoracic vibrations caused by the cardiac contraction and ejection of blood into the great vessels. Current smartphones with gyroscopes and accelerometers can measure these vibrations. Based on these components we measure and quantify the cardiac kinetic energy (kinocardiography) in order to differentiate dyspnea of cardiac origin from dyspnea of other origin. The study is conducted in an emergency service where a smartphone performs the measurement during 3 minutes. The results of the kinocardiography-based classification are then compared to the final diagnosis made by a physician. Currently, 235 patients have been included in the clinical study since May 2022. This rapid and non-invasive measurement allows the aid-to-diagnosis of heart failure without being influenced by other factors like the renal function for example that can be NT-pro BNP blood marker.

Official Title
-----------------
KINO-DYSPNEA: Validation of Kinocardiography to Distinguish Dyspnea of Cardiac Origin From Others

Conditions
-----------------
Dyspnea

Intervention / Treatment
-----------------
* Device: Kinocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dyspnea. Adults aged above 18 years old. Exclusion Criteria: Patients younger than 18 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Kinocardiography|Smartphone (application with seismocardiography)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the ability of the Kinocardiography technique to discriminate cardiac caused dyspnea from others. | Area under the receiver operating characteristic curve (AUROC), negative predictive value (NPV) and specificity, with two-sided 95% CIs. | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Open retrospective exploratory study to validate the physiological interpretation of Kinocardiography in a clinical environment. | Establish a link between cardiac kinetic energy distribution in the cardiac cycle between major active clinical syndromes that may be concomitant in the field of cardiac disorders (hypertension, atrial fibrillation, ischemia, valvulopathy, heart-failure,…) and pulmonary (asthma, infection,..). These clinical diagnoses are supported by the physical examination and the patient's medical record at inclusion, with the aid of a measurement of troponin and NTBNP | 18 months |
RDW to Platlet Count Ratio in CKD Patients

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to determine Red blood cell distribution width to platelet count ratio as a predictor of cardiovascular complications in CKD patients

Detailed Description
-----------------
comparative study between RDW to Platlet count ratio in CKD patients without cardiovascular complications and CKD patients with cardiovascular complications

Official Title
-----------------
Red Blood Cell Distribution Width to Platelet Count Ratio as a Predictor of Cardiovascular Complications in CKD Patients

Conditions
-----------------
Cardiovascular Complication

Intervention / Treatment
-----------------
* Diagnostic Test: RDW to platlet count ratio


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CKD Patients and patients receive dialysis >18 years old Exclusion Criteria: Serious complications of any other organs patients who had previously undergone kidney transplantation . CKD patients with history of previous CVD patients with an infection, blood transfusion or receiving immunosuppressive drugs, as this may have affected the inflammatory response within the 3 months patients who were pregnant patients with chronic hematological disease patient<18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1-CKD patients without cardiovascular complications<br> | Diagnostic Test: RDW to platlet count ratio<br>* RDW to platlet ratio will be measured for all patients and results will be compared between groups<br>|
| 2-CKD patients with cardiovascular complications<br> | Diagnostic Test: RDW to platlet count ratio<br>* RDW to platlet ratio will be measured for all patients and results will be compared between groups<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of results of RDW to platlet ratio in CKD patients | Calculate RDW to platlet ratio for CKD patints with or without cardiovascular complications and compare the results | 1 year |
Correction of Psoriatic T Cell Signatures by Deucravacitinib

Study Overview
=================
Brief Summary
-----------------
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Detailed Description
-----------------
This is a one-arm, open-label study to examine the effect of deucravacitinib on cutaneous and blood immune cells of psoriatic patients. 25 subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for deucravacitinib-corrected signatures.

Official Title
-----------------
Correction of Psoriatic T Cell Signatures by Deucravacitinib

Conditions
-----------------
Psoriasis Vulgaris

Intervention / Treatment
-----------------
* Drug: deucravacitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Patients with moderate-severe psoriasis (BSA >= 10%, PASI >=12, static Physician's Global Assessment (sPGA) 3 and above) Exclusion Criteria: taking systemic immunosuppressives in the last 12 weeks pregnancy severe immunodeficiency (either from genetic or infectious causes). tuberculosis or other active serious infection active systemic malignancy. breast-feeding Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: deucravacitinib treatment<br>treatment with deucravacitinib for 6 months | Drug: deucravacitinib<br>* Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Psoriasis Area and Severity Index (PASI) score | Change in severity and extent of psoriasis (calculated by Psoriasis Area and Severity Index (PASI) score); scale range of 0 to 72, 72 being maximal disease | pre-treatment, 4 months |
Multimodal Ultrasound Diagnosis Characteristics of Bi-rads Class 4 Breast Lesions

Study Overview
=================
Brief Summary
-----------------
Objective: To explore the potential association between the multimodal ultrasound characteristics and pathological classification of BI-RADS category 4 breast lesions, so as to clarify the diagnostic characteristics of multimodal ultrasound in different pathological types BI-RADS category 4 breast lesions. Materials and methods: Patients who visited in The First Affiliated Hospital of Shandong First Medical University ＆ Shandong Provincial Qianfoshan Hospital were collected. Their general clinical features, information on preoperative ultrasound diagnosis, and postoperative pathologic data were reviewed.

Official Title
-----------------
Correlation Between Multi-modal Ultrasound Features and Pathologic Classification of BI-RADS Category 4 Breast Lesions

Conditions
-----------------
Breast Disease

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Perform ultrasound examination at our hospital before surgery or puncture biopsy; Complete histopathological data; Two ultrasound physicians with more than 5 years of experience in breast ultrasound diagnosis were diagnosed as BI-RADS Class 4 based on preoperative ultrasound images. Exclusion Criteria: Poor image quality; Incomplete clinical data.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 76 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| fibroadenoma group<br> | Other: no intervention<br>* no intervention<br>|
| breast hyperplasia group<br> | Other: no intervention<br>* no intervention<br>|
| other types of benign nodules group<br> | Other: no intervention<br>* no intervention<br>|
| non-specific invasive carcinoma group<br> | Other: no intervention<br>* no intervention<br>|
| other types of breast cancer group<br> | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| elasticity imaging/B-mode ratio | The ratio of lesion length on strain elastography images to lesion length on grayscale images | Immediately record the elastic modulus value after the patient receives routine ultrasound and shear wave elastography | 
| shear wave velocity | Shear wave velocity values at the hardest point of the lesion and surrounding tissues | Immediately record the elastic modulus value after the patient receives routine ultrasound and shear wave elastography | 
| strain ratio | The ratio of average strain between surrounding tissues at the same depth and the lesion | Immediately record the elastic modulus value after the patient receives routine ultrasound and shear wave elastography |
Bloodpressure and NIRS During the Immediate Transition

Study Overview
=================
Brief Summary
-----------------
Blood pressure will be measured in min. 5/10/15 after birth. Cerebral tissue oxygenation (crSO2) monitoring with NIRS in addition to routine arterial oxygen saturation (SpO2) monitoring with pulse oximetry will be performed continuously during the first 15 minutes after birth

Official Title
-----------------
Arterial Blood Pressure and Cerebral Tissue Oxygenation During Immediate Transition After Birth in Term and Preterm Neonates - a Prospective Pilot Observational Study

Conditions
-----------------
Blood Pressure, Cerebral Tissue Oxygenation

Intervention / Treatment
-----------------
* Diagnostic Test: Cerebral tissue oxygenation and blood pressure measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Term and preterm neonates observed routinely immediately after birth at the resuscitation desk Decision to conduct full life support Written informed consent Exclusion Criteria: No decision to conduct full life support No written informed consent Congenital malformation

Ages Eligible for Study
-----------------
Minimum Age: 1 Minute
Maximum Age: 15 Minutes

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Term neonates<br>Neonates with gestational age 37+0 - 42+0 weeks | Diagnostic Test: Cerebral tissue oxygenation and blood pressure measurement<br>* Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth<br>|
| Preterm neonates<br>Neonates with gestational age < 37+0 weeks | Diagnostic Test: Cerebral tissue oxygenation and blood pressure measurement<br>* Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure | Systolic, diastolic and mean blood pressure in mmHg measured with a pneumatic cuff | 5, 10 and 15 minutes after birth | 
| Cerebral oxygenation | Cerebral tissue oxygen saturation in percent measured with NIRS | 5, 10 and 15 minutes after birth | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac output | Calculated out of blood pressure and heart rate | 5, 10 and 15 minutes after birth |
The Effects Of Low Intensity Training With Blood Flow Restriction In Rheumatoid Arthritis Patients

Study Overview
=================
Brief Summary
-----------------
Rheumatoid arthritis (RA) patients showed systemic manifestations that may lead to a reduction in muscle strength, muscle mass and, consequently, to a reduction in physical function. On the other hand, high intensity resistance training (HIRT) are able to improve muscle strength and muscle mass in RA without affecting the disease course. However, due to the articular manifestations caused by this disease, these patients may present intolerance to HIRT. Thus, the low intensity resistance training with blood flow restriction (TBFR) may be a new training strategy for these populations. In this sense, the investigators speculate that TBFR could be beneficial in RA patients, as well as, HIRT.

Official Title
-----------------
The Effects Of Low Intensity Training With Blood Flow Restriction In The Lower And Upper Limbs On Muscle Strength, Muscle Mass, Biochemical Parameters And Markers Of Systemic Inflammation In Rheumatoid Arthritis Patients: A Randomized Clinical Trial

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Other: High intensity resistance training
* Other: Low intensity resistance training combined with blood flow restriction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female; Rheumatoid arthritis patients; All individuals will undergo an ergospirometry to ensure cardiorespiratory conditions. Exclusion Criteria: Fibromyalgia; Cardiovascular disease;

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High intensity resistance training<br> | Other: High intensity resistance training<br>* Twelve weeks of resistance training twice a week.<br>|
| Experimental: Low intensity resistance training combined with blood flow restriction<br> | Other: Low intensity resistance training combined with blood flow restriction<br>* Twelve weeks of resistance training with blood flow restriction twice a week.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle strength | 1 maximum repetition test. | Twelve weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rheumatoid Arthritis, Kaatsu, Blood Flow Restriction Training
Post-operative Thoracic Epidural Analgesia and Incidence of Major Complications: a Large Retrospective Dual Center Experi-ence

Study Overview
=================
Brief Summary
-----------------
A retrospective observational dual center study investigating side effects and major complications after thoracic epidural insertion according to local safety protocols.

Detailed Description
-----------------
Abstract: (1) Background: Thoracic epidural analgesia is considered the gold standard in post-operative pain management following thoracic surgery. This study was designed to explore the safety of thoracic epidural analgesia and to quantify the incidence of its post-operative side-effects in patients undergoing thoracotomy for major surgery, such as resection of lung malignancies and lung transplantation. (2) Methods: This is a retrospective, dual-center observa-tional study implementing patients that underwent major thoracic surgery including lung trans-plantation and received concurrent placement of thoracic epidural catheters for postoperative an-algesia. An electronic system of referral and documentation of complications was used, and information was retrieved from our electronic critical care charting system. Side effects such as nausea and vomiting , itching, catheter related issues and also major complications such as epidural haematoma, abscess, or permanent nerve damage were investigated. The study aims to highlight the importance of a solid documentation and recording system alongside with the implementation of safety protocols.

Official Title
-----------------
Post-operative Thoracic Epidural Analgesia and Incidence of Major Complications: a Large Retrospective Dual Center Experi-ence

Conditions
-----------------
Neuropathic Pain, Chronic Pain, Thoracic Cancer

Intervention / Treatment
-----------------
* Procedure: thoracic epidural insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. All patients undergoing major thoracic surgery ASA1-3 2. All patients undergoing lung transplantation Exclusion Criteria: 1. Active bleeding 2. Coagulopathy 3. High inflammatory markers 4. SIRS 5. Lack of patients' consent for throracic epidural insertion -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: thoracic epidural insertion|thoracic epidural for pain relief after major thoracic surgery and lung transplantation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of major complications |  | 3 YEARS |